Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Stig Præstekjær Cramer"'
Autor:
Amalie Monberg Hindsholm, Flemming Littrup Andersen, Stig Præstekjær Cramer, Helle Juhl Simonsen, Mathias Gæde Askløf, Melinda Magyari, Poul Nørgaard Madsen, Adam Espe Hansen, Finn Sellebjerg, Henrik Bo Wiberg Larsson, Annika Reynberg Langkilde, Jette Lautrup Frederiksen, Liselotte Højgaard, Claes Nøhr Ladefoged, Ulrich Lindberg
Publikováno v:
Frontiers in Neuroscience, Vol 17 (2023)
IntroductionPatients with MS are MRI scanned continuously throughout their disease course resulting in a large manual workload for radiologists which includes lesion detection and size estimation. Though many models for automatic lesion segmentation
Externí odkaz:
https://doaj.org/article/316b298a0d4344bc8a6af99d908ccf6a
Autor:
Maria Højberg Knudsen, Ulrich Lindberg, Jette Lautrup Frederiksen, Mark Bitsch Vestergaard, Helle Juhl Simonsen, Aravinthan Varatharaj, Ian Galea, Morten Blinkenberg, Finn Sellebjerg, Henrik Bo Wiberg Larsson, Stig Præstekjær Cramer
Publikováno v:
Knudsen, M H, Lindberg, U, Frederiksen, J L, Vestergaard, M B, Simonsen, H J, Varatharaj, A, Galea, I, Blinkenberg, M, Sellebjerg, F, Larsson, H B W & Cramer, S P 2022, ' Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis ', Multiple Sclerosis and Related Disorders, vol. 63, 103891 . https://doi.org/10.1016/j.msard.2022.103891
Background: In relapsing-remitting multiple sclerosis (RRMS), early disease control reduces the risk of permanent disability. The blood–brain barrier (BBB) is compromised in MS, and its permeability is a potential biomarker. Objective: To investiga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7467e44ca05d08ef7be4df12b698ed33
https://doi.org/10.1016/j.msard.2022.103891
https://doi.org/10.1016/j.msard.2022.103891